The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users

@article{Bijl2008TheCP,
  title={The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users},
  author={Monique J. Bijl and Ron van Schaik and Laureen A. Lammers and Albert Hofman and Arnold Vulto and Teun van Gelder and Bruno C. Stricker and Loes E. Visser},
  journal={Breast Cancer Research and Treatment},
  year={2008},
  volume={118},
  pages={125-130}
}
Cytochrome P450 2D6 (CYP2D6) plays an important role in the formation of endoxifen, the active metabolite of tamoxifen. In this study the association between the most prevalent CYP2D6 null-allele in Caucasians (CYP2D6*4) and breast cancer mortality was examined among all incident users of tamoxifen in a population-based cohort study. Breast cancer mortality was significantly increased in patients with the * 4/*4 genotype (HR = 4.1, CI 95% 1.1–15.9, P = 0.041) compared to wild type patients. The… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 51 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 29 references

a modeling analysis

  • RS Punglia, HJ Burstein, EP Winer, CYP2D6 Weeks JC Pharmacogenomic variation of, cancer the choice of optimal adjuvant endocrine therapy f breast
  • J Natl Cancer Inst 100(9):642–648. doi: 10.1093…
  • 2009
1 Excerpt

Genetic variants of CYP3A5, CYP2D6, Breast Cancer Res Treat

  • P Wegman, S Elingarami, J Carstensen, O Stal, B Nordenskjold, S Wingren
  • Breast Cancer Res 9(1):R7. doi: 10.1186/bcr1640
  • 2007
1 Excerpt

Similar Papers

Loading similar papers…